Musculoskeletal Disorders
Conference Coverage
AVXS-101 may result in long-term motor improvements in SMA
CHARLOTTE, N.C. – Data indicate continuous expression of the SMN protein among treated patients.
From the Journals
Psoriasis risk rises with TNF inhibitor use in children with inflammatory disorders
“These data reflect the established association between inflammatory conditions and psoriasis development and suggest that TNFi exposure further...
Perspectives
CBD: What physicians need to know about it
An internist describes the benefits and risks of using cannabidiol to treat various conditions.
From the Journals
Juvenile dermatomyositis derails growth and pubertal development
Delayed puberty and growth failure were observed in children with juvenile dermatomyositis.
Conference Coverage
Mechanism does not matter for second-line biologic choice in JIA
MADRID – There was no difference in effectiveness outcomes or drug survival when switching to a second biologic with an alternate mechanism of...
Conference Coverage
Emapalumab produces major responses in macrophage activation syndrome
MADRID – In systemic juvenile idiopathic arthritis complicated by MAS, new therapy produces rapid complete responses.
Video
Efforts toward producing CNO/CRMO classification criteria show first results
MADRID – Cases are now being accepted for inclusion into a repository that will be used to develop and validate criteria.
From the Journals
When adolescents visit the ED, 10% leave with an opioid
Compared with outpatient clinics, prescription rate is more than six times higher in the emergency department.
Guidelines
New JIA, JIA-associated uveitis guidelines address knowledge gaps
A majority of recommendations in both guidelines are called conditional based on low-quality evidence.
Daily News Podcast
Opioids don’t top NSAIDs for chronic pain
And canakinumab has a remarkable effect on knee and hip replacement risk.
From the Journals
Drug-free inactive disease a feasible goal in JIA
Among patients with a recent onset of JIA, 71% had inactive disease (median onset 9 months) and 39% were drug free.